Compare ARK Innovation ETF (ARKK) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Innovation ETF vs Enveric Biosciences Inc — how do they compare? ARK Innovation ETF trades at $80.61, while Enveric Biosciences Inc trades at $1.45 (market cap $6.20M). The key difference: ARK Innovation ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ARKK | ENVB | |
|---|---|---|
52-Week High | $92.50 | $17.40 |
52-Week Low | $63.52 | $1.27 |
Market Cap | — | $6.20M |
Sector | — | Health |
Enterprise Value | — | $1.30M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARK Innovation ETF (ARKK) trades at $79.43, up 4.89% today with strong technical momentum as moving averages signal bullish alignment. The ETF faces mixed sentiment with recent Seeking Alpha articles highlighting concentration risks in SpaceX and Tesla holdings while Cathie Wood continues aggressive AI stock purchases. Technical indicators show RSI at overbought levels near 82, suggesting potential near-term consolidation despite the bullish trend.
Outlook remains polarized between innovation optimism and valuation concerns. The fund's heavy exposure to speculative tech names offers growth potential but carries significant volatility risk. Recent underperformance versus broad market indices and high fee structure present headwinds, while continued institutional interest in disruptive technologies provides long-term catalysts.
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Innovation ETF
The fund will invest under normal circumstances primarily (at least 65% of its assets) in domestic and foreign equity securities of companies that are relevant to the fund’s investment theme of disruptive innovation. Its investments in foreign equity securities will be in both developed and emerging markets. The fund may invest in foreign securities listed on foreign exchanges as well as American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs). The fund is non-diversified.
Read more on ARKK →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
